SHH:688578
Shanghai Allist Pharmaceuticals Co., Ltd. · SHH · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 13:35 UTC
Last close
n/aCNY
Market data
18.0xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
34.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
42.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
0.001Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
Price is the furthest below its sector's middle: 0.34 against 0.36 on the market's range.
- Growth521.2%88 of 100, above its sector
- Returns on capital34.6%95 of 100, above its sector
- Margins96.8%98 of 100, above its sector
- Price18.0x34 of 100, below its sector
- Safety0.00194 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Then and now
lens 3 of 9| Fact | 2017 | 2025 | Change |
|---|---|---|---|
| Sales | 7,727,000 | 5,187,338,133 | +67,033% |
| Profit | -38,933,801 | 2,181,293,000 | +5,703% |
| Free cash flow | 8,716,820 | n/a | n/a |
| Debt | 60,000,000 | 3,887,763 | -93.5% |
| Shares in issue | n/a | 449,751,113 | n/a |
The same five facts for 2017 and 2025, each read from the year's own filing.
The same five facts for 2017 and 2025, each read from the year's own filing.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2017
Sales, 20177,727,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2017
- Reported in
- CNY
Sales, 20255,187,338,133Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Profit, 2017-38,933,801
- Source
- computed
- Statement
- income
- Fiscal year
- 2017
- Reported in
- CNY
Profit, 20252,181,293,000Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Free cash flow, 20178,716,820
- Source
- computed
- Statement
- income
- Fiscal year
- 2017
- Reported in
- CNY
Free cash flow, 2025n/aComputed from the filing for 2025
Not held.
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Debt, 201760,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2017
- Reported in
- CNY
Debt, 20253,887,763Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Shares in issue, 2017n/a
Not held.
- Source
- computed
- Statement
- income
- Fiscal year
- 2017
- Reported in
- CNY
Shares in issue, 2025449,751,113Computed from the filing for 2025
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY